Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.040x

Based on the latest financial reports, Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2) has a cash flow conversion efficiency ratio of 0.040x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€52.44 Billion ≈ $61.30 Billion USD) by net assets (€1.30 Trillion ≈ $1.52 Trillion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see RIG2 company net worth for the company's overall valuation and market capitalisation.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt ranked by their cash flow conversion efficiency. Explore Richter Gedeon Vegyészeti Gyár Nyilvános cash flow quality index to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
SICC Co. Ltd.
SHG:688234
-0.030x
Huaibei Mining Holdings Co Ltd
SHG:600985
0.038x
Baiyin Nonferrous Group Co Ltd
SHG:601212
0.041x
PSP Swiss Property AG
SW:PSPN
0.007x
Metallurgical Corporation of China Ltd
SHG:601618
0.019x
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607
0.017x
SBI Cards and Payment Services Limited
NSE:SBICARD
0.007x
Informatica Inc
NYSE:INFA
0.061x

Annual Cash Flow Conversion Efficiency for Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (2013–2025)

The table below shows the annual cash flow conversion efficiency of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt from 2013 to 2025. View Richter Gedeon Vegyészeti Gyár Nyilvános stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €1.40 Trillion
≈ $1.64 Trillion
€276.40 Billion
≈ $323.14 Billion
0.197x -7.91%
2024-12-31 €1.30 Trillion
≈ $1.52 Trillion
€279.37 Billion
≈ $326.61 Billion
0.214x +67.87%
2023-12-31 €1.14 Trillion
≈ $1.34 Trillion
€145.84 Billion
≈ $170.50 Billion
0.128x -26.81%
2022-12-31 €1.06 Trillion
≈ $1.24 Trillion
€184.93 Billion
≈ $216.20 Billion
0.174x +15.06%
2021-12-31 €923.02 Billion
≈ $1.08 Trillion
€139.90 Billion
≈ $163.56 Billion
0.152x -7.60%
2020-12-31 €813.94 Billion
≈ $951.58 Billion
€133.52 Billion
≈ $156.10 Billion
0.164x +21.07%
2019-12-31 €724.87 Billion
≈ $847.45 Billion
€98.21 Billion
≈ $114.82 Billion
0.135x -7.41%
2018-12-31 €685.75 Billion
≈ $801.71 Billion
€100.34 Billion
≈ $117.31 Billion
0.146x +16.02%
2017-12-31 €664.02 Billion
≈ $776.31 Billion
€83.75 Billion
≈ $97.91 Billion
0.126x +11.08%
2016-12-31 €681.87 Billion
≈ $797.18 Billion
€77.42 Billion
≈ $90.51 Billion
0.114x -26.13%
2015-12-31 €618.39 Billion
≈ $722.96 Billion
€95.05 Billion
≈ $111.12 Billion
0.154x +38.81%
2014-12-31 €561.73 Billion
≈ $656.72 Billion
€62.20 Billion
≈ $72.72 Billion
0.111x -17.46%
2013-12-31 €551.20 Billion
≈ $644.41 Billion
€73.94 Billion
≈ $86.45 Billion
0.134x --

About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt

F:RIG2 Germany Drug Manufacturers - Specialty & Generic
Market Cap
$7.57 Billion
€6.47 Billion EUR
Market Cap Rank
#2999 Global
#588 in Germany
Share Price
€35.48
Change (1 day)
+1.60%
52-Week Range
€24.60 - €37.02
All Time High
€37.02
About

Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chron… Read more